Pratt, Alexandre J.
Purssell, Andrew
Zhang, Tinghua
Luks, Vanessa P. J.
Bauza, Xavier
Mulpuru, Sunita
Kirby, Miranda
Aaron, Shawn D.
Cowan, Juthaporn
Article History
Received: 14 May 2023
Accepted: 28 July 2023
First Online: 14 August 2023
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki. Included patients in this study were identified from a prospective pilot randomized controlled trial (IPRAC) that aimed to determine feasibility of monthly intravenous immunoglobulin infusions for one year to prevent recurrent AECOPD in hospitalized patients with AECOPD from Sep 2016 to Mar 2018 [CitationRef removed]. The IPRAC study received institutional approval from the Ottawa Health Science Network Research Ethics Board (Protocol 20150925-01H, 20160077-01H, and 2017005-01H), which allowed for retrospective analysis of collected data from patients screened for eligibility. Written informed consent was obtained from participants who were eligible to the prospective IPRAC trial.
: Not applicable.
: JC received honoraria from GSK, Merck, Sanofi Genzyme, Takeda, CSL Behring, Biogen unrelated to this work. MK is a consultant for VIDA Diagnostics Inc. (Coralville, IA, USA). AJP, AP, TZ, VL, XB, SM, SDA do not have competing interests.